Trial Profile
A study of evaluation to the predictive biomarker of Nivolumab in peripheral blood and pleural effusion.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 07 Mar 2022 Status changed from recruiting to completed.
- 21 Sep 2016 New trial record